ZYMEWORKS INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
ZYMEWORKS INC. (ZYME) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$35.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-06
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$130.00K, a 296.97% decline year-over-year.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was $95.00K, a 62.45% decline year-over-year.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was -$25.00K.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $290.00K, a 84.78% decline year-over-year.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$293.00K, a 623.21% decline from fiscal 2023.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $56.00K.
- ZYMEWORKS INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$35.00K 10-Q · filed 2026-08-06 | -$60.00K derived: sum of 3 quarters · filed 2026-08-06 | $230.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $95.00K 10-Q · filed 2026-05-07 | $70.00K derived: sum of 2 quarters · filed 2026-08-06 | $360.00K derived: sum of 3 quarters · filed 2026-08-06 | $426.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$25.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | $265.00K derived: sum of 2 quarters · filed 2026-08-06 | $331.00K derived: sum of 3 quarters · filed 2026-08-06 | $584.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $356.00K derived: sum of 2 quarters · filed 2025-11-06 | $609.00K 10-Q · filed 2025-11-06 | -$344.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $319.00K 10-Q · filed 2025-08-07 | -$634.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $253.00K 10-Q · filed 2025-05-08 | -$700.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.21M derived: sum of 3 quarters · filed 2026-03-02 | $1.02M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $952.00K derived: sum of 2 quarters · filed 2026-03-02 | $772.00K derived: sum of 3 quarters · filed 2026-03-02 | -$293.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.73M derived: sum of 2 quarters · filed 2024-10-31 | $660.00K 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.25M 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | -$1.06M 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $56.00K 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |